visceral adiposity is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-04. Numbers and descriptions here follow the published literature rather than marketing material.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
The following table shows the electron configuration of a neutral gas-phase atom of each element. Different configurations can be favoured in different chemical environments. The main-group elements have entirely regular electron configurations; the transition and inner transition elements show twenty irregularities due to the aforementioned competition between subshells close in energy level. For the last ten elements (109–118), experimental data is lacking and therefore calculated configurations have been shown instead. Completely filled subshells have been greyed out.
Several naturally-preserved, unintentional mummies dating from the Incan period (1438–1532 AD) have been found in the colder regions of Argentina, Chile, and Peru. These are collectively known as "ice mummies". The first Incan ice mummy was discovered in 1954 atop El Plomo Peak in Chile, after an eruption of the nearby volcano Sabancaya melted away ice that covered the body. The Mummy of El Plomo was a male child who was presumed to be wealthy due to his well-fed bodily characteristics. He was considered to be the most well-preserved ice mummy in the world until the discovery of Mummy Juanita in 1995. Mummy Juanita was discovered near the summit of Ampato in the Peruvian section of the Andes mountains by archaeologist Johan Reinhard. Her body had been so thoroughly frozen that it had not been desiccated; much of her skin, muscle tissue, and internal organs retained their original structure. She is believed to be a ritual sacrifice, due to the close proximity of her body to the Incan capital of Cusco, as well as the fact she was wearing highly intricate clothing to indicate her special social status. Several Incan ceremonial artifacts and temporary shelters uncovered in the surrounding area seem to support this theory. More evidence that the Inca left sacrificial victims to die in the elements, and later be unintentionally preserved, came in 1999 with the discovery of the Llullaillaco mummies on the border of Argentina and Chile. The three mummies are children, two girls and one boy, who are thought to be sacrifices associated with the ancient ritual of qhapaq hucha.
Adequate sleep duration and quality have been linked to lower cardiometabolic risk, with insufficient sleep associated with higher rates of hypertension, obesity, and dysregulated glucose metabolism. Reducing alcohol intake may also be protective, as heavy use can worsen hepatic and metabolic outcomes in people with underlying metabolic risk. Although individual-level changes are effective for many people, adherence varies widely in real-world settings. Public-health bodies—including the International Obesity Taskforce—argue that sustained prevention requires population-level interventions, such as improved access to healthy foods, urban design that supports physical activity, and policies addressing socioeconomic drivers of obesity.
Sources: en.wikipedia.org
== Ion and atom sources == Sources can be adapted in many ways, but the lists below give the general uses of a number of sources. Of these, flames are the most common due to their low cost and their simplicity. Although significantly less common, inductively-coupled plasmas, especially when used with mass spectrometers, are recognized for their outstanding analytical performance and their versatility. For all atomic spectroscopy, a sample must be vaporized and atomized. For atomic mass spectrometry, a sample must also be ionized. Vaporization, atomization, and ionization are often, but not always, accomplished with a single source. Alternatively, one source may be used to vaporize a sample while another is used to atomize (and possibly ionize). An example of this is laser ablation inductively-coupled plasma atomic emission spectrometry, where a laser is used to vaporize a solid sample and an inductively-coupled plasma is used to atomize the vapor. With the exception of flames and graphite furnaces, which are most commonly used for atomic absorption spectroscopy, most sources are used for atomic emission spectroscopy. Liquid-sampling sources include flames and sparks (atom source), inductively-coupled plasma (atom and ion source), graphite furnace (atom source), microwave plasma (atom and ion source), and direct-current plasma (atom and ion source). Solid-sampling sources include lasers (atom and vapor source), glow discharge (atom and ion source), arc (atom and ion source), spark (atom and ion source), and graphite furnace (atom and vapor source).
Meanwhile, according to 2013 European Society of Cardiology (ESC) guidelines, a loop diuretic can only replace thiazide-type diuretics if there is renal impairment (Creatinine of more than 1.5 mg/dL or estimated glomerular filtration rate (eGFR) of less 30 mL/min/1.73 m2 due to lack of long term cardiovascular outcome data and appropriate dosing regimen of its use. The 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guidelines stated that diuretics should not be used to treat acute kidney injury, except for the management of volume overload. Diuretics has not shown any benefits of preventing or treating acute kidney injury. They are also sometimes used in the management of severe hypercalcemia in combination with adequate rehydration.
=== Medication shortages === Trends on TikTok have contributed to the shortages of some medications. Danish pharmaceutical company Novo Nordisk produces three medications containing the active ingredient semaglutide. One of the drugs, Wegovy, is certified by the Food and Drug Administration for the treatment of obesity. The other two, Ozempic and Rybelsus, are only certified for the treatment of diabetes. In 2022, the United States suffered shortages of Ozempic after it became a trend on the platform to use the medication off-label for its weight loss effects. Australia's Therapeutic Goods Administration reported that Ozempic's popularity on TikTok had contributed to a global shortage of the medication. It recommended that doctors not prescribe the medication to new patients and prescribe alternative medications to existing patients where possible. By March 2023, TikTok videos posted with the hashtag #Ozempic had amassed 690 million views.
Polyester has high glass-transition temperature Tg and high melting point Tm, good mechanical properties to about 175 °C, and good resistance to solvents and chemicals. It can exist as fibers and films. The former is used in garments, felts, tire cords, etc. The latter appears in magnetic recording tape and high-grade films. Polyamide (nylon) has good balance of properties: high strength, good elasticity, abrasion resistance, good toughness, favorable solvent resistance. The applications of polyamide include rope, belting, fiber cloths, thread, substitute for metal in bearings, jackets on electrical wire, and more. Polyurethane can exist as elastomers with good abrasion resistance, hardness, good resistance to grease, and good elasticity, as fibers with excellent rebound, as coatings with good resistance to solvent attack and abrasion, and as foams with good strength, good rebound, and high impact strength. Polyurea shows high Tg, fair resistance to greases, oils, and solvents. It can be used in truck bed liners, bridge coatings, caulk, and decorative designs. Polysiloxane, siloxane-based polymers available in a wide range of physical states—from liquids to greases, waxes, resins, and rubbers. Due to perfect thermal stability (thanks to silicon), uses of this material include antifoam and release agents, gaskets, seals, cable and wire insulation, hot liquids and gas conduits, etc. Polycarbonates are transparent, self-extinguishing materials. They possess properties like crystalline thermoplasticity, high impact strength, and good thermal and oxidative stability.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.